Automating bacterial identification and antibiotic-susceptibility plate reading
Choosing an effective antibiotic requires identifying the bacteria causing an infection and testing their susceptibility. Culture-based bacterial identification remains time-consuming and labor-intensive, even as laboratory automation reduces some manual work.
Baio-dx is developing automated bacterial identification and antibiotic-susceptibility plate reading using holographic imaging and AI. Its system analyzes bacteria directly on agar plates to support microbiology laboratories within existing culture workflows.
What stands out about Baio-dx
At 18 hours, a prototype assigned species to 201/232 clinical isolates across 10 trained species, with 96.5% agreement among assigned results.
In 2022, CEA confirmed that Baio-dx held licences to four CEA patents supporting its holographic microbiology technology.
CEA reports a partnership with Grenoble Alpes University Medical Center to test patient samples using a Baio-dx prototype.
Baio-dx identifies itself as a CEA and CNRS spin-off, incorporated in January 2022 following their microbiology research collaboration.
Won recognition in the i-Lab strand of France's 2022 innovation competition, organized by the state with Bpifrance.
Co-founders Stéphane Buisson and Jordan Belissard also co-founded Canopus AI, acquired by Siemens in January 2026.
Bpifrance supported the published bacterial-identification study through the i-Lab innovation competition.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.